Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Although one patient treated with Ocrevus has reportedly developed PML, Roche blamed this on previous treatment with Tysabri. And while Biogen’s Tecfidera (dimethyl fumarate) pill is also ...

The APPA, if passed into law, puts an upper limit of 20 patents, but only of certain types of patents (see below), that can be asserted in a BPCIA litigation (the APPA does not affect ANDA litigations ...

Fampridine, which is approved to improve walking in MS patients, and Ocrevus may help ease walking impairments, a review of ...

A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting experienced no evidence of disease activity for as long as ...